Neuraxis Inc 's

The competitive landscape includes off-label drugs and FDA-approved treatments for adults with irritable bowel syndrome (IBS), but no FDA-indicated therapies exist for patients aged 8 to 21 with functional abdominal pain associated with IBS. Psychological treatments such as cognitive behavioral therapy (CBT) and guided imagery have demonstrated effectiveness but are limited by access to trained therapists. The company addresses this limitation by providing guided-imagery audio in conjunction with its IB-Stim device. The neurostimulation market is primarily composed of surgically implanted, invasive technologies, which are not directly competitive with the company’s non-invasive technology. Several large, publicly traded neurostimulation companies have established product pipelines and greater access to capital; however, none currently target the central nervous system or brain-gut axis via auricular nerves for functional bowel disorders or IBS. The company holds patents on the Neuraxis method, which protects access to the brain through cranial nerves in the ear. Competitive advantages include being first to market, a strong portfolio of device and method patents, large market opportunities, a robust pediatric pipeline, inclusion in academic society guidelines as the only FDA-approved or FDA-cleared recommended treatment, a Category I CPT code effective January 1, 2026, and strong clinical data from leading U.S. academic institutions. Growth strategies involve a list price of $1,195 per device and $4,780 per patient, maintaining strong gross margins, employing a direct sales force, and targeting children’s hospitals, adult gastroenterologists within the Veterans Affairs system, and adult pain physicians.